S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BPTH

Bio-Path (BPTH) Stock Price, News & Analysis

$4.04
+0.02 (+0.50%)
(As of 03/27/2024 ET)
Today's Range
$4.00
$4.14
50-Day Range
$3.87
$9.40
52-Week Range
$3.51
$44.80
Volume
11,311 shs
Average Volume
22,537 shs
Market Capitalization
$2.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Bio-Path MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
890.1% Upside
$40.00 Price Target
Short Interest
Bearish
9.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Bio-Path in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($20.80) to ($15.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

BPTH stock logo

About Bio-Path Stock (NASDAQ:BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock Price History

BPTH Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Bio-Path Shares Close Lower After Withdrawing S-1
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
Bio-Path Holdings's Earnings: A Preview
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Bio Path Holdings Inc (BPTH)
Bio-Path Holdings Inc.
BPTH Bio-Path Holdings, Inc.
Bio-Path files to sell shares
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
3/27/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
2007

Profitability

Net Income
$-16,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.71 per share

Miscellaneous

Free Float
658,000
Market Cap
$2.75 million
Optionable
Optionable
Beta
0.66

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 75)
    Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
    Comp: $722.68k
  • Mr. Douglas P. Morris (Age 68)
    Co-Founder, Director of Investor Relations, Secretary & Director
    Comp: $110.68k
  • Mr. Michael Hickey M.B.A.
    VP of Clinical Operations
  • Mr. Anthony Price
    Senior Vice President of Finance, Accounting & Administration
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Senior Vice President of Research, Development & Clinical Design

BPTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

What is Bio-Path's stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for Bio-Path's shares. Their BPTH share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 890.1% from the stock's current price.
View analysts price targets for BPTH
or view top-rated stocks among Wall Street analysts.

How have BPTH shares performed in 2024?

Bio-Path's stock was trading at $9.26 at the beginning of 2024. Since then, BPTH shares have decreased by 56.4% and is now trading at $4.04.
View the best growth stocks for 2024 here
.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 63,400 shares, an increase of 284.2% from the February 29th total of 16,500 shares. Based on an average daily volume of 21,200 shares, the days-to-cover ratio is currently 3.0 days. Currently, 9.6% of the company's stock are short sold.
View Bio-Path's Short Interest
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Friday, March, 8th. The company reported ($5.40) earnings per share for the quarter, meeting analysts' consensus estimates of ($5.40). During the same quarter in the prior year, the company earned ($10.60) earnings per share.

When did Bio-Path's stock split?

Bio-Path shares reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (39.71%) and Vanguard Group Inc. (2.19%).
View institutional ownership trends
.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPTH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners